NCT06077773

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria (CALM-CSU)

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 113 (actual)
• Sponsor: Escient Pharmaceuticals, Inc · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects with Chronic Spontaneous Urticaria

Conditions

• Chronic Spontaneous Urticaria

Interventions

Type	Name	Description
DRUG	Oral EP262	Once daily
DRUG	Placebo	Once daily

Timeline

• Start date: 2023-09-25
• Primary completion: 2024-12-18
• Completion: 2025-01-16
• First posted: 2023-10-11
• Last updated: 2025-12-19
• Results posted: 2025-12-05

Locations

48 sites across 6 countries: United States, Canada, Germany, Netherlands, Poland, Spain

Regulatory

• FDA-regulated drug study